Industry readers: a timely briefing on how emerging biotech firms leverage external expertise to refine development priorities and investor narratives.
Key Takeaways
- Junevity engaged Sunrise BioVentures advisors to accelerate development of its siRNA therapeutics
- Advisory team will support preclinical validation, pipeline strategy, and business development
- JUN_01 reduced inflammation, improved glycemic markers, and targets a Phase 1 trial in late 2026